On October 12, 2026, Bristol Myers Squibb reported positive late-stage trial results for two experimental drugs targeting rare cancers and lung disease. Actinium-225 therapy RYZ101 significantly delayed progression in gastrointestinal and pancreatic neuroendocrine tumors, while a 60 mg dose of LPA1 inhibitor admilparant preserved lung function in idiopathic pulmonary fibrosis patients. The successes offer a boost to the company's drug pipeline as it faces revenue losses from impending patent expirations.
Phase 3 trial results for admilparant
- ▪Bristol Myers Squibb announced on October 12, 2026 that a 60 mg twice-daily dose of admilparant met its primary endpoint by slowing forced vital capacity decline in a 1,255-patient idiopathic pulmonary fibrosis trial
- ▪In Bristol Myers Squibb's late-stage idiopathic pulmonary fibrosis trial, the higher 120 mg dose of admilparant failed to meet the study's primary endpoint of preserving lung function
Late-stage trial results for RYZ101
- ▪Bristol Myers Squibb reported that the safety profile of RYZ101 was consistent with previous RYZ101 studies and that the company planned to discuss the RYZ101 trial data with regulatory authorities
- ▪Bristol Myers Squibb's RYZ101 trial tested the therapy against standard-of-care treatments in gastroenteropancreatic neuroendocrine tumor patients whose disease had progressed following Lutetium-177-based therapy
- ▪Bristol Myers Squibb stated on October 12, 2026 that its experimental radiopharmaceutical cancer therapy RYZ101 significantly delayed disease progression in late-stage trial patients with gastroenteropancreatic neuroendocrine tumors
RYZ101 clinical trials
- ▪Bristol Myers Squibb did not disclose detailed data from its late-stage RYZ101 study, stating that results will be presented at a future medical meeting
- ▪Bristol Myers Squibb is also testing its actinium-225 therapy RYZ101 in early-stage clinical trials for hormone receptor-positive metastatic breast cancer
Analyst reaction to RYZ101 results
- ▪RBC Capital Markets analysts stated that the RYZ101 study results validate Bristol Myers Squibb's radiopharmaceutical platform and may boost confidence in rival radiopharmaceutical development programs across the pharmaceutical sector
- ▪Cantor Fitzgerald analyst Carter Gould cautioned that RYZ101 may be only a modest commercial driver for Bristol Myers Squibb as newer lead-212 alpha-emitting therapies advance into earlier treatment lines
Broader radiopharmaceutical market context
- ▪Wall Street is evaluating whether RYZ101 and competing radiopharmaceutical drugs can build upon the commercial and clinical success established by Novartis' radiopharmaceutical drugs
- ▪Major pharmaceutical companies including AstraZeneca and Eli Lilly have invested heavily in radiopharmaceutical therapies that deliver targeted radioactive isotopes, such as actinium-225 used by Bristol Myers Squibb's RYZ101, to tumorous tissue
Market reaction and pipeline importance
- ▪Wall Street analysts had been anticipating Bristol Myers Squibb's late-stage trial results because the experimental drugs RYZ101 and admilparant target hard-to-treat, fatal conditions and serve as potential boons for its new product pipeline
- ▪Positive trial results for experimental lung disease and cancer therapies could help Bristol Myers Squibb offset pending revenue losses from upcoming patent expirations on major drugs
- ▪Bristol Myers Squibb shares rose over 3% in premarket trading and were trading up nearly 2% on October 12, 2026 following positive late-stage trial announcements for admilparant and RYZ101
Debatable claims
- ▪Bristol Myers should release detailed clinical data concurrently with major trial success announcements
- ▪RYZ101's trial success validates targeted radiopharmaceutical cancer therapies
- ▪The high-dose trial failure weakens admilparant's therapeutic promise for lung disease
Story comments
Loading comments…